Success examples
Native Mass Spectrometry Analysis of Cullin RING Ubiquitin E3 Ligase Complexes in the Context of Targeted Protein Degradation

Sternicki L. M., Crowe C., Wieske L. H. E., Ciulli A., Poulsen S-A.

bioRxiv. 2026, 12.04.692288.

BET PROTAC
DOI
PubMed
General literature
Complex I Modulator BI4500 Reduces MASH by Limiting Oxidative Stress and Reprogramming Lipid Metabolism via AMPK in MCD Rats

Di Pasqua L. G., Lotti S., Trucchi M., Palladini G., Croce A. C., Protopapa F., Feletti F., Kauschke S. G., Sun P., Vairetti M., Ferrigno A.

Antioxidants (Basel). 2026, 15(1):82.

DOI
PubMed
General literature
Mapping the functional connectome of the claustrum: Noise filtering via local inhibitory circuits

Graf M., Sadeh S., Augustine G. J.

Cell Rep. 2026, 45(1):116821.

DOI
PubMed
Success examples
Systematic Application of a Cellular Thermal Shift Assay for Inferring Inhibitor Binding Affinity to 17βHSD13 in a Humanized Liver Homogenate

Lunnerdal S., Wågberg F., Dahl G., Ahnmark A., Hansson P., Sampers E., Madeyski-Bengtson K., Lee W., Löfgren L., Zarrouki B., Hallén S., Lundbäck T. 

Biochemistry. 2026, 65(3):311-324.

HSD17B13 inhibitor
DOI
PubMed
Success examples
Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting

Damghani T., Song S., Lin K. S., Li J., Heppner D. E.

ACS Medicinal Chemistry Letters 2026.

4th gen EGFR inhibitor
DOI
Success examples
Mixed Lineage Kinase Domain-Like Protein (MLKL): From Mechanisms to Therapeutic Opportunities

Xu L., Zhuang C.

Adv Sci (Weinh). 2025, 12(35):e09277.

MLKL inhibitor
DOI
PubMed